Q3 FY26 results: Revenue up 15% YoY, declares Re.1 interim dividend
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 9.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amrutanjan Health Care posted Q3 FY26 revenue of Rs.141.04 cr (up 14.9% YoY) and PAT of Rs.19.45 cr (up 1.1% YoY). For 9M FY26, revenue rose 11.5% to Rs.352.78 cr and PAT grew 17% to Rs.41.73 cr. Board declared a second interim dividend of Re.1 per share. An exceptional item of Rs.1.25 cr was booked for new labour codes impact. Auditors BSR and Co LLP issued an unmodified limited review report.
Steady revenue growth with modest profit uptick. Re.1 dividend is positive for shareholders. Labour code charge is a one-time item.